Impact of switching virologically suppressed, HIV-1-infected patients from twice-daily fixed-dose zidovudine/lamivudine to once-daily fixed-dose tenofovir disoproxil fumarate/emtricitabine

HIV Clinical Trials

Volumn 9, Issue 2, 2008, Pages 103-114

  DeJesus, Edwin ^a   Ruane, Peter ^b   McDonald, Cheryl ^c   Garcia, Fernando ^d   Sharma, Shetal ^e   Corales, Roberto ^f   Ravishankar, Jayashree ^g   Khanlou, Homayoun ^h   Shamblaw, David ⁱ   Ecker, Janet ^a   Ebrahimi, Ramin ^a   Flaherty, John ^a  

^a ORLANDO IMMUNOLOGY CENTER   (United States)

^b Lightsource Medical Group   (United States)

^c Radiol Associates of Tarrant County   (United States)

^d Valley AIDS Council   (United States)

^e North Broward Hospital District   (United States)

^f AIDS Community Health Center Rochester   (United States)

^g SUNY DOWNSTATE MEDICAL CENTER   (United States)

^h AIDS HEALTHCARE FOUNDATION   (United States)

ⁱ Gilead Sciences Inc ^*

Author keywords

AZT 3TC; TDF FTC; Treatment simplification

Indexed keywords

EFAVIRENZ; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; LAMIVUDINE PLUS ZIDOVUDINE;

ABDOMINAL PAIN; ADULT; AGED; ANXIETY; ARTICLE; BACKACHE; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; CREATINE KINASE BLOOD LEVEL; DEMOGRAPHY; DEPRESSION; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSURIA; FATIGUE; FEMALE; FLATULENCE; HEADACHE; HEMATURIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE RESPONSE; INSOMNIA; INTESTINE DISTENSION; KIDNEY PAIN; MAJOR CLINICAL STUDY; MALE; MALNUTRITION; MULTICENTER STUDY; NAUSEA AND VOMITING; NERVOUSNESS; OSTEOPOROSIS; PAIN; PARESTHESIA; PATIENT SATISFACTION; POLYURIA; PRIORITY JOURNAL; QUALITY OF LIFE; RISK FACTOR; SELF REPORT; SIDE EFFECT; SKIN TINGLING; SPONTANEOUS ABORTION; UPPER RESPIRATORY TRACT INFECTION; VIRUS LOAD; XEROSTOMIA;

ADENINE; ADULT; AGED; ANTI-RETROVIRAL AGENTS; CREATININE; DEOXYCYTIDINE; FEMALE; HEMOGLOBINS; HIV INFECTIONS; HIV-1; HUMANS; LAMIVUDINE; LIPIDS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; PATIENT COMPLIANCE; PATIENT SATISFACTION; PHOSPHONIC ACIDS; QUALITY OF LIFE; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD; ZIDOVUDINE;

EID: 44949105260     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/hct0902-103     Document Type: Article

References (25)

1. Chesney M. Adherence to HAART regimens. AIDS Patient Care STDS. 2003; 17:169-177.
2. Liu H, Miller LG. Hays RD, et al. Repeated measures longitudinal analyses of HIV virologic response as a function of percent adherence, dose timing, genotypic sensitivity, and other factors. J Acquir Immune Defic Syndr. 2006;41:315-322.
3. Maggiolo F, Ravasio L, Ripamonti D, et al. Similar adherence rates favor different virologic outcomes for patients treated with nonnucleoside analogues or protease inhibitors. Clin Infect Dis. 2005;40:158-163.
4. Staszewski S, Morales-Ramirez J, Tashima KT, et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. N Engl J Med. 1999;341:1865-1873.
5. DeJesus E, Herrera G, Teofilo E, et al. Abacavir versus zidovudine combined with lamivudine and efavirenz, for treatment of antiretroviral- naïve HIV-infected adults. Clin Infect Dis. 2004; 39:1038-1046.
6. Gallant JE, DeJesus E, Arribas JR, et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med. 2006;354:251-260.
7. Gallant JE, Parish MA, Keruly JC, Moore RD. Changes in renal function associated with tenofovir disoproxil fumarate, compared with nucleoside reverse transcriptase inhibitor treatment. Clin Infect Dis. 2005;40:1194-1198.
8. Fisher M, Moyle G, Ebrahimi R, and the SWEET Study Group. Switching from Combivir (CBV, AZT/3TC) to Truvada (TVD, TDF/FTC) maintains viral suppression, prevents and reverses limb fat loss, and improves biochemical parameters: Results of a 48 week randomised study. In: Program and abstracts of the 11th European AIDS Conference; October 24-27, 2007; Madrid, Spain. Abstract PS5/7.
9. Sklar PA, Ward DJ, Baker RK, et al. Prevalence and clinical correlates of HIV viremia ("blips") in patients with previous suppression below the limits of quantification. AIDS. 2002;16:2035-2041.
10. Nettles RE, Keiffer TL, Kwon P, et al. Intermittent HIV-1 viremia (blips) and drug resistance in patients receiving HAART. JAMA. 2005;293:817-829.
11. Stosor V, Palella FJ, Berzins B, Till M, et al. Transient viremia in HIV-infected patients and use of plasma preparation tubes. Clin Infect Dis. 2005;41:1671-1674.
12. Giordano M, Kelleher T, Colonno RJ, et al. The effects of the Roche AMPLICOR HIV1 MONITOR® Ultrasensitive Test versions 1.0 and 1.5 viral load assays and plasma collection tube type on determination of response to antiretroviral therapy and the inappropriateness of cross-study comparisons. J Clin Virol. 2006;35:420-425.
13. Drechsler H, Powderly WG. Switching effective antiretroviral therapy: a review. Clin Infect Dis. 2002;35:1219-1230.
14. McComsey GA, Ward DJ, Hessenthaler SM, et al. Improvements in lipoatrophy associated with highly active antiretroviral therapy in human immunodeficiency virus-infected patients switched from stavudine to abacavir or zidovudine: the results of the TARHEEL Study. Clin Infect Dis. 2004;38:263-270.
15. Llibre JM, Domingo R, Palacios R, et al. Sustained improvement of dyslipidaemia in HAART-treated patients replacing stavudine with tenofovir. AIDS. 2006;20:1407-1414.
16. Carr A, Workman C, Smith DE, et al. Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy. JAMA. 2002;288:207-215.
17. Moyle, GJ, Sabin C, Cartledge J, Johnson M, et al. A randomized, controlled trial of tenofovir DF or abacavir as replacement for thymidine analogue in persons with lipoatrophy. AIDS. 2006;20:2043-2050.
18. Moyle G, Sawyer W, Law M, et al. Changes in hematologic parameters and efficacy of thymidine analogue-based, highly active antiretroviral therapy: a meta-analysis of six, prospective, randomized, comparative studies. Clin Ther. 2004;26:92-97.
19. Molina JM, Bentata M, Garré M, et al., and the ALIZE study group. Hematologic benefit of switching from regimens combining protease inhibitors and zidovudine plus lamivudine to once-daily emtricitabine, didanosine, and efavirenz. A sub-study of the ANRS 099 ALIZE trial. In: Program and abstracts of the 12th Conference on Retroviruses and Opportunistic Infections; February 22-25, 2005; Boston, MA. Abstract 830.
20. Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs. stavudine in combination therapy in antiretroviral naïve patients: a 3-year randomized trial. JAMA. 2004;292:191-201.
21. Cassetti I, Madruga JVR, Suleiman JMAH, et al. The safety and efficacy of tenofovir DF in combination with lamivudine and efavirenz through 6 years in antiretroviral naïve HIV-1 infected patients. HIV Clin Trials. 2007;8:164-172.
22. Pozniak AL, Gallant JE, DeJesus E, et al. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral naïve patients. Virologic, imunologic, and morphologic changes: a 96 week analysis. J Acquir Immune Defic Syndr. 2006;43:535-540.
23. Zimmerman AE, Pizzoferrato T, Bedford J, et al. Tenofovir-associated acute and chronic kidney disease: a case of multiple drug interactions. Clin Infect Dis. 2006;42:283-290.
24. Molina JM, Journot V, Morand-Joubert L, et al. Simplification therapy with once daily emtricitabine, didanosine, and efavirenz in HIV-1-infected adults with viral suppression receiving a protease inhibitor-based regimen: a randomized trial. Clin Infect Dis. 2005;191:830-839.
25. Stone VE, Jordan J, Tolson J, et al. Perspectives on adherence and simplicity for HIV-infected patients on antiretroviral therapy. J Acquir Immune Defic Syndr. 2004;36:808-816.